Previous 10 | Next 10 |
Last week we talked about biotech penny stocks with upcoming catalysts. That article received a lot of attention and for obvious reasons. As I explained, few industries will host companies that will tell you when they’ve got news coming. Biotech is one of these industries, and it...
MaxCyte has become the go-to partner for biotech companies using non-viral cell engineering, aided by its proprietary patented flow electroporation technology. The company has a scalable (licenses and SPLs) business model with recurring revenues. Milestone and royalty payments (at 100...
Precigen to Present at the 2021 Wells Fargo Virtual Healthcare Conference and the H.C. Wainwright 23rd Annual Global Investment Conference PR Newswire GERMANTOWN, Md. , Sept. 1, 2021 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company s...
Precigen, Inc. (PGEN) Q2 2021 Results Earnings Conference Call August 09, 2021, 04:05 PM ET Company Participants Steven Harasym - Vice President, IR Helen Sabzevari - President & CEO Conference Call Participants Nick Abbott - Wells Fargo Jason Butler - JMP Securities Ben Burnett - Stifel ...
Image source: The Motley Fool. Precigen, inc (NASDAQ: PGEN) Q2 2021 Earnings Call Aug 9, 2021 , 4:05 p.m. ET Operator Continue reading For further details see: Precigen, inc (PGEN) Q2 2021 Earnings Call Transcript
Precigen Reports Second Quarter and First Half 2021 Financial Results - Company to provide comprehensive clinical pipeline and data updates at R&D call on November 4th - PR Newswire GERMANTOWN, Md. , Aug. 9, 2021 /PRNewswire/ -- Precigen, Inc. (Nasdaq...
Precigen to Announce Second Quarter and First Half 2021 Financial Results on August 9th PR Newswire GERMANTOWN, Md. , Aug. 2, 2021 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene an...
primeimages/E+ via Getty Images Tesla (TSLA) was in the spotlight Friday following the formal launch of its latest electric car model. At the same time, a handful of stocks posted big premarket moves as a result of drug development news. This included Noven (NOVN), Precigen (PGEN), and Vertex...
Precigen's (PGEN) soars 28% premarket after its wholly-owned subsidiary, Precigen ActoBio reported positive topline results for Phase 1b/2a clinical study investigating AG019 ActoBiotics for the treatment of recent-onset type 1 diabetes (T1D).The primary endpoint of treatment-emergi...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, investors! We’re approaching the end of trading for the week but we’ve got one more day of market coverage to bring you. Of course, we’re starting that off with a look at the biggest pre-m...
News, Short Squeeze, Breakout and More Instantly...
2024-06-03 14:30:04 ET Stifel Nicolaus analyst issues MARKET OUTPERFORM recommendation for PGEN on June 3, 2024 01:00PM ET. The previous analyst recommendation was Market Outperform. PGEN was trading at $1.53 at issue of the analyst recommendation. The overall analyst co...
2024-06-03 14:30:03 ET JMP Securities analyst issues UNDERPERFORM recommendation for PGEN on June 3, 2024 01:00PM ET. The previous analyst recommendation was Underperform. PGEN was trading at $1.53 at issue of the analyst recommendation. The overall analyst consensus : B...
Precigen Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More than Half of Patients Achieved Complete Response PR Newswire – Phase 1/2 pivotal study met the primary safety and efficacy endpoints ...